IMPACTT

The purpose of this study is to prolong the time to reinfection with Pseudomonas aeruginosa after successfully treated acute or intermittent infection.

Disease: Cystic fibrosis

Study phase: III

ECRIN support role: Advice and information

Monitoring

Local pharmacovigilance

Regulatory and ethical submission

Study/trial status: Recruitment/follow-up

Expected patient number: 180 patients

Sponsor: Mukoviszidose Institut gGmbH

Sponsor type: Academic

Principal investigator (PI): Antje Schuster

Current participating countries: Austria, Belgium, France, Germany, Hungary, Italy, Poland, Spain, Sweden

Trial identifier(s): NCT NCT01455675

EudraCT 2011-000801-39